Symbols

TNDM

Tandem Diabetes Care·NASDAQ

--(--)

TNDM fundamentals

TNDM Q4 2025 Earnings

Tandem Diabetes Care (TNDM) released its earnings on Feb 19, 2026: revenue was 290.38M (YoY +15.03%), beat estimates; EPS was -0.0087 (YoY -187.00%), beat estimates.

Revenue / YoY

290.38M

+15.03%

EPS / YoY

-0.0087

-187.00%

Report date

Feb 19, 2026

TNDM Earnings Call Summary for Q4,2025

Record 2025 Performance: $1.015 billion revenue (+12% YoY), Q4 sales $290 million (+15% YoY)
Strategic PayGo Transition: 20% U.S. pumps via PayGo by end-2026, targeting 70%+ long-term
Gross Margin Expansion: 56-57% in 2026 (vs. 54% in 2025)
International Growth: Direct Europe operations driving 15%+ international sales growth
Innovation Pipeline: Mobi Tubeless FDA submission Q2, fully closed-loop trial planned for 2026

Earnings

EPS

Revenue

Revenue & Expenses

TNDM has released its 2025 Q4 earnings report, with revenue of 290.38M, reflecting a YoY change of 2.74%, and net profit of -589.00K, showing a YoY change of -178.01%. The Sankey diagram below clearly presents TNDM's revenue sources and cost distribution.

Key Indicators

Tandem Diabetes Care (TNDM) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Tandem Diabetes Care (TNDM)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Tandem Diabetes Care (TNDM)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Tandem Diabetes Care (TNDM)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown